JP2015521643A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015521643A5 JP2015521643A5 JP2015519035A JP2015519035A JP2015521643A5 JP 2015521643 A5 JP2015521643 A5 JP 2015521643A5 JP 2015519035 A JP2015519035 A JP 2015519035A JP 2015519035 A JP2015519035 A JP 2015519035A JP 2015521643 A5 JP2015521643 A5 JP 2015521643A5
- Authority
- JP
- Japan
- Prior art keywords
- pain
- disorder
- disease
- pharmaceutically acceptable
- schizophrenia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000002193 Pain Diseases 0.000 claims 11
- 230000036407 pain Effects 0.000 claims 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 9
- 208000035475 disorder Diseases 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 4
- 230000036541 health Effects 0.000 claims 4
- 208000004296 neuralgia Diseases 0.000 claims 4
- 208000021722 neuropathic pain Diseases 0.000 claims 4
- LUEYUHCBBXWTQT-UHFFFAOYSA-N 4-phenyl-2h-triazole Chemical class C1=NNN=C1C1=CC=CC=C1 LUEYUHCBBXWTQT-UHFFFAOYSA-N 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 201000000980 schizophrenia Diseases 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 2
- 206010012289 Dementia Diseases 0.000 claims 2
- 201000010374 Down Syndrome Diseases 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 2
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims 2
- 208000020016 psychiatric disease Diseases 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 1
- VQVLEDQDCNRDNQ-UHFFFAOYSA-N 6-[[5-(difluoromethyl)-3-(4-fluorophenyl)triazol-4-yl]methoxy]pyridazine-3-carboxamide Chemical compound N1=NC(C(=O)N)=CC=C1OCC1=C(C(F)F)N=NN1C1=CC=C(F)C=C1 VQVLEDQDCNRDNQ-UHFFFAOYSA-N 0.000 claims 1
- 208000030507 AIDS Diseases 0.000 claims 1
- 208000000103 Anorexia Nervosa Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 206010003805 Autism Diseases 0.000 claims 1
- 208000020706 Autistic disease Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 206010006895 Cachexia Diseases 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- 208000017164 Chronobiology disease Diseases 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 208000024254 Delusional disease Diseases 0.000 claims 1
- 208000030814 Eating disease Diseases 0.000 claims 1
- 206010015958 Eye pain Diseases 0.000 claims 1
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 1
- 208000001640 Fibromyalgia Diseases 0.000 claims 1
- 206010072132 Fracture pain Diseases 0.000 claims 1
- 208000011688 Generalised anxiety disease Diseases 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- 208000004454 Hyperalgesia Diseases 0.000 claims 1
- 208000035154 Hyperesthesia Diseases 0.000 claims 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims 1
- 206010061216 Infarction Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000026139 Memory disease Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 208000019022 Mood disease Diseases 0.000 claims 1
- 208000016285 Movement disease Diseases 0.000 claims 1
- 206010028289 Muscle atrophy Diseases 0.000 claims 1
- 206010028391 Musculoskeletal Pain Diseases 0.000 claims 1
- 208000028389 Nerve injury Diseases 0.000 claims 1
- 208000009668 Neurobehavioral Manifestations Diseases 0.000 claims 1
- 208000003019 Neurofibromatosis 1 Diseases 0.000 claims 1
- 208000024834 Neurofibromatosis type 1 Diseases 0.000 claims 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000004983 Phantom Limb Diseases 0.000 claims 1
- 206010056238 Phantom pain Diseases 0.000 claims 1
- 208000004550 Postoperative Pain Diseases 0.000 claims 1
- 208000028017 Psychotic disease Diseases 0.000 claims 1
- 208000005793 Restless legs syndrome Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 206010043269 Tension headache Diseases 0.000 claims 1
- 208000008548 Tension-Type Headache Diseases 0.000 claims 1
- 208000031674 Traumatic Acute Stress disease Diseases 0.000 claims 1
- 206010044688 Trisomy 21 Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 208000026345 acute stress disease Diseases 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 208000007502 anemia Diseases 0.000 claims 1
- 208000022531 anorexia Diseases 0.000 claims 1
- 230000002917 arthritic effect Effects 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 230000007278 cognition impairment Effects 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 206010061428 decreased appetite Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 206010013663 drug dependence Diseases 0.000 claims 1
- 208000029364 generalized anxiety disease Diseases 0.000 claims 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims 1
- 230000007574 infarction Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 206010027175 memory impairment Diseases 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 230000020763 muscle atrophy Effects 0.000 claims 1
- 201000000585 muscular atrophy Diseases 0.000 claims 1
- 230000008764 nerve damage Effects 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 230000003349 osteoarthritic effect Effects 0.000 claims 1
- 208000019906 panic disease Diseases 0.000 claims 1
- 208000002851 paranoid schizophrenia Diseases 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- DMYLUKNFEYWGCH-UHFFFAOYSA-N pyridazine-3-carboxamide Chemical compound NC(=O)C1=CC=CN=N1 DMYLUKNFEYWGCH-UHFFFAOYSA-N 0.000 claims 1
- 230000020341 sensory perception of pain Effects 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 208000020685 sleep-wake disease Diseases 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 208000011117 substance-related disease Diseases 0.000 claims 1
- 230000000472 traumatic effect Effects 0.000 claims 1
- 208000009935 visceral pain Diseases 0.000 claims 1
- 208000016261 weight loss Diseases 0.000 claims 1
- 230000004580 weight loss Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261664288P | 2012-06-26 | 2012-06-26 | |
| DKPA201270369 | 2012-06-26 | ||
| DKPA201270369 | 2012-06-26 | ||
| US61/664,288 | 2012-06-26 | ||
| PCT/EP2013/063194 WO2014001282A1 (en) | 2012-06-26 | 2013-06-25 | A phenyl triazole derivative and its use for modulating the gabaa receptor complex |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015521643A JP2015521643A (ja) | 2015-07-30 |
| JP2015521643A5 true JP2015521643A5 (enExample) | 2016-08-12 |
| JP6223443B2 JP6223443B2 (ja) | 2017-11-01 |
Family
ID=49782300
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015519035A Expired - Fee Related JP6223443B2 (ja) | 2012-06-26 | 2013-06-25 | フェニルトリアゾール誘導体及びｇａｂａａ受容体複合体を調節するための該フェニルトリアゾール誘導体の使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US9475797B2 (enExample) |
| EP (1) | EP2885290B1 (enExample) |
| JP (1) | JP6223443B2 (enExample) |
| KR (1) | KR20150033679A (enExample) |
| CN (1) | CN104411703A (enExample) |
| AU (1) | AU2013283488A1 (enExample) |
| BR (1) | BR112014032501A2 (enExample) |
| CA (1) | CA2876780A1 (enExample) |
| IL (1) | IL235991A (enExample) |
| IN (1) | IN2014DN11027A (enExample) |
| MX (1) | MX2014014872A (enExample) |
| RU (1) | RU2014149123A (enExample) |
| WO (1) | WO2014001282A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR102019014802A2 (pt) * | 2018-07-20 | 2020-02-04 | Boehringer Ingelheim Int | difluorometil-fenil triazóis |
| TWI901650B (zh) | 2020-03-26 | 2025-10-21 | 匈牙利商羅特格登公司 | 啶及吡啶并〔３，４－ｃ〕嗒衍生物 |
| CN115461337A (zh) * | 2020-05-13 | 2022-12-09 | 豪夫迈·罗氏有限公司 | 作为GABA A α5 PAM的新型三唑基衍生物 |
| JP7802256B2 (ja) * | 2020-08-05 | 2026-01-20 | サニオナ アクティーゼルスカブ | ジフルオロメチル－ピリジン－２－イルトリアゾール |
| HU231691B1 (hu) | 2021-09-29 | 2025-10-28 | Richter Gedeon Nyrt | GABAA ALFA5 receptor modulátor hatású biciklusos aminszármazékok |
| CN116462664B (zh) * | 2022-03-08 | 2025-07-01 | 上海赛默罗生物科技有限公司 | 吡唑环类化合物、其制备方法、组合物及应用 |
Family Cites Families (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69627195T2 (de) | 1995-11-01 | 2004-01-29 | Novartis Ag | Purinderivate und verfahren zu ihrer herstellung |
| FR2741881B1 (fr) | 1995-12-01 | 1999-07-30 | Centre Nat Rech Scient | Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques |
| WO1999032454A1 (en) | 1997-12-22 | 1999-07-01 | Du Pont Pharmaceuticals Company | Nitrogen containing heteroaromatics with ortho-substituted p1's as factor xa inhibitors |
| DE19834044A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
| CA2394654A1 (en) | 1999-12-17 | 2001-06-21 | Manfred Weigele | Proton pump inhibitors |
| AU2441701A (en) | 1999-12-17 | 2001-06-25 | Ariad Pharmaceuticals, Inc. | Purine derivatives |
| JP2004501062A (ja) | 1999-12-17 | 2004-01-15 | アライアッド・ファーマシューティカルズ・インコーポレーテッド | 新規プリン類 |
| WO2003002565A1 (en) | 2001-06-27 | 2003-01-09 | Cyclacel Limited | 2,6,9-substituted purine derivatives and their use n the treatment of proliferative disorders |
| US7262176B2 (en) | 2001-08-08 | 2007-08-28 | Cv Therapeutics, Inc. | Adenosine A3 receptor agonists |
| US20030078232A1 (en) | 2001-08-08 | 2003-04-24 | Elfatih Elzein | Adenosine receptor A3 agonists |
| US20060009642A1 (en) | 2001-10-12 | 2006-01-12 | Irm Llc, A Delaware Limited Liability Company | Methods for the synthesis of substituted purines |
| CA2463563A1 (en) | 2001-10-12 | 2003-04-17 | Irm Llc | Kinase inhibitor scaffolds and methods for their preparation |
| US20030229105A1 (en) | 2002-05-21 | 2003-12-11 | Cyclacel Limited | Treatment of autoimmune disorders |
| US20030139427A1 (en) | 2002-08-23 | 2003-07-24 | Osi Pharmaceuticals Inc. | Bicyclic pyrimidinyl derivatives and methods of use thereof |
| WO2004021979A2 (en) | 2002-09-06 | 2004-03-18 | Smithkline Beecham Corporation | PYRROLO[2, 3-d]PYRIMIDINE-4-YL AND PURIN-6-YL UREA COMPOUNDS |
| US20050124637A1 (en) | 2003-08-15 | 2005-06-09 | Irm Llc | Compounds and compositions as inhibitors of receptor tyrosine kinase activity |
| US20050239806A1 (en) | 2004-01-13 | 2005-10-27 | Ambit Biosciences Corporation | Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases |
| TW200538120A (en) | 2004-02-20 | 2005-12-01 | Kirin Brewery | Compound having TGF-beta inhibitory activity and pharmaceutical composition containing same |
| GB0407723D0 (en) | 2004-04-05 | 2004-05-12 | Novartis Ag | Organic compounds |
| FR2876583B1 (fr) | 2004-10-15 | 2007-04-13 | Centre Nat Rech Scient Cnrse | Utilisation de derives de purines pour la fabrication de medicaments pour le traitement de la mucoviscidose et de maladies liees a un defaut d'adressage des proteines dans les cellules |
| GB0500785D0 (en) | 2005-01-14 | 2005-02-23 | Novartis Ag | Organic compounds |
| US8252806B2 (en) | 2005-03-14 | 2012-08-28 | Neurosearch A/S | Potassium channel modulating agents and their medical use |
| GB0505219D0 (en) | 2005-03-14 | 2005-04-20 | Novartis Ag | Organic compounds |
| US20090036475A1 (en) | 2005-03-22 | 2009-02-05 | Neurosearch A/S | Pyrazolyl-Pyrimidines as Potassium Channel Modulating Agents and Their Medical Use |
| WO2006125211A1 (en) | 2005-05-19 | 2006-11-23 | Cv Therapeutics, Inc. | A1 adenosine receptor agonists |
| JP2009508905A (ja) | 2005-09-19 | 2009-03-05 | エフ．ホフマン−ラ ロシュ アーゲー | ＧＡＢＡＡα５逆アゴニストとしてのイソオキサゾロ誘導体 |
| WO2007042420A1 (en) | 2005-10-11 | 2007-04-19 | F. Hoffmann-La Roche Ag | Isoxazole derivatives |
| AU2006311092B2 (en) | 2005-11-09 | 2011-05-12 | F. Hoffmann-La Roche Ag | 3-aryl-isoxazole-4-carbonyl-benzofuran derivatives |
| EP1966184B1 (en) | 2005-12-20 | 2010-08-25 | NeuroSearch A/S | Pyridinyl-quinazoline derivatives and their medical use |
| CN101346372B (zh) | 2005-12-23 | 2011-09-28 | 弗·哈夫曼-拉罗切有限公司 | 芳基-异*唑-4-基-*二唑衍生物 |
| WO2007074078A2 (en) | 2005-12-27 | 2007-07-05 | F. Hoffmann-La Roche Ag | Aryl-isoxazol-4-yl-imidazole derivatives |
| BRPI0620760A2 (pt) | 2005-12-27 | 2011-11-22 | Hoffmann La Roche | derivados de aril-isoxazol-4-il-imidazo[1,5]piridina |
| DE602007005256D1 (de) * | 2006-05-24 | 2010-04-22 | Lilly Co Eli | Verbindungen und verfahren zur modulierung von fx-rezeptoren |
| KR101119365B1 (ko) | 2006-05-31 | 2012-03-07 | 에프. 호프만-라 로슈 아게 | 아릴-4-에틴일-아이속사졸 유도체 |
| EP1894924A1 (en) | 2006-08-29 | 2008-03-05 | Phenex Pharmaceuticals AG | Heterocyclic FXR binding compounds |
| EP1894928A1 (en) | 2006-08-29 | 2008-03-05 | PheneX Pharmaceuticals AG | Heterocyclic fxr binding compounds |
| EP2066655A2 (en) | 2006-09-07 | 2009-06-10 | Neurosearch A/S | Pyridinyl-pyrimidine derivatives useful as potassium channel modulating agents |
| WO2008040753A1 (en) | 2006-10-03 | 2008-04-10 | Neurosearch A/S | Indazolyl derivatives useful as potassium channel modulating agents |
| EP2124954A2 (en) | 2007-01-26 | 2009-12-02 | Irm Llc | Purine compounds and compositions as kinase inhibitors for the treatment of plasmodium related diseases |
| EP2114916A2 (en) | 2007-02-02 | 2009-11-11 | NeuroSearch A/S | Pyridinyl-pyrazole derivatives and their use as potassium channel modulators |
| JP2010522722A (ja) | 2007-03-28 | 2010-07-08 | ノイロサーチ アクティーゼルスカブ | プリニル誘導体及びカリウムチャネルモジュレーターとしてのそれらの使用 |
| CA2682019C (en) | 2007-03-28 | 2016-08-09 | Neurosearch A/S | Purinyl derivatives and their use as potassium channel modulators |
| ES2369805T3 (es) | 2007-06-22 | 2011-12-07 | F. Hoffmann-La Roche Ag | Derivados de isoxazol-imidazol. |
| WO2009050199A1 (en) | 2007-10-17 | 2009-04-23 | Novartis Ag | Purine derivatives as adenosine al receptor ligands |
| MX2010005753A (es) | 2007-12-04 | 2010-06-15 | Hoffmann La Roche | Derivados de isoxazolo-pirazina. |
| US7943619B2 (en) * | 2007-12-04 | 2011-05-17 | Hoffmann-La Roche Inc. | Isoxazolo-pyridazine derivatives |
| JP5301557B2 (ja) | 2007-12-04 | 2013-09-25 | エフ．ホフマン−ラ ロシュ アーゲー | イソオキサゾロ−ピリジン誘導体 |
| EP2128158A1 (en) | 2008-05-26 | 2009-12-02 | Phenex Pharmaceuticals AG | Heterocyclic cyclopropyl-substituted FXR binding compounds |
| EA019755B1 (ru) * | 2008-06-19 | 2014-06-30 | Такеда Фармасьютикал Компани Лимитед | Гетероциклическое соединение и его применение |
| WO2010034707A1 (en) | 2008-09-26 | 2010-04-01 | Neurosearch A/S | Substituted purinyl-pyrazol derivatives and their use as potassium channel modulators |
| US20110237607A1 (en) | 2008-09-26 | 2011-09-29 | Neurosearch A/S | Substituted purinyl-pyrazol derivatives and their use as potassium channel modulators |
| PE20100362A1 (es) | 2008-10-30 | 2010-05-27 | Irm Llc | Derivados de purina que expanden las celulas madre hematopoyeticas |
| US8389550B2 (en) | 2009-02-25 | 2013-03-05 | Hoffmann-La Roche Inc. | Isoxazoles / O-pyridines with ethyl and ethenyl linker |
| US8222246B2 (en) | 2009-04-02 | 2012-07-17 | Hoffmann-La Roche Inc. | Substituted isoxazoles |
| US20100280019A1 (en) | 2009-04-30 | 2010-11-04 | Roland Jakob-Roetne | Isoxazoles |
| AU2010244545A1 (en) * | 2009-05-05 | 2011-10-13 | F. Hoffmann-La Roche Ag | Isoxazole-pyridazine derivatives |
| SG175867A1 (en) | 2009-05-05 | 2011-12-29 | Hoffmann La Roche | Isoxazole-pyridine derivatives |
| BRPI1011729A2 (pt) | 2009-05-05 | 2016-03-15 | Hoffmann La Roche | derivados de isoxazol-tiazol como um receptor inverso gaba a agonista para uso no tratamento de distúrbios cognitivos |
| EP2427455B1 (en) | 2009-05-05 | 2020-01-15 | F.Hoffmann-La Roche Ag | Isoxazole-pyrazole derivatives |
| AU2010244555A1 (en) | 2009-05-07 | 2011-11-03 | F. Hoffmann-La Roche Ag | Isoxazole-pyridine derivatives as GABA modulators |
| EP2289883A1 (en) | 2009-08-19 | 2011-03-02 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
| BR112013011265A2 (pt) * | 2010-11-09 | 2016-11-01 | Hoffmann La Roche | derivados de triazol como ligantes para receptores gaba |
| US8742097B2 (en) * | 2010-11-09 | 2014-06-03 | Hoffmann-La Roche Inc. | Triazole compounds I |
| US8466181B2 (en) | 2010-12-10 | 2013-06-18 | Hoffmann-La Roche Inc. | 1,2,3-triazole-imidazole compounds |
-
2013
- 2013-06-25 AU AU2013283488A patent/AU2013283488A1/en not_active Abandoned
- 2013-06-25 US US14/411,326 patent/US9475797B2/en not_active Expired - Fee Related
- 2013-06-25 KR KR20157001895A patent/KR20150033679A/ko not_active Withdrawn
- 2013-06-25 RU RU2014149123A patent/RU2014149123A/ru not_active Application Discontinuation
- 2013-06-25 CN CN201380034072.1A patent/CN104411703A/zh active Pending
- 2013-06-25 EP EP13730899.5A patent/EP2885290B1/en not_active Not-in-force
- 2013-06-25 WO PCT/EP2013/063194 patent/WO2014001282A1/en not_active Ceased
- 2013-06-25 JP JP2015519035A patent/JP6223443B2/ja not_active Expired - Fee Related
- 2013-06-25 IN IN11027DEN2014 patent/IN2014DN11027A/en unknown
- 2013-06-25 CA CA2876780A patent/CA2876780A1/en not_active Abandoned
- 2013-06-25 BR BR112014032501A patent/BR112014032501A2/pt not_active IP Right Cessation
- 2013-06-25 MX MX2014014872A patent/MX2014014872A/es unknown
-
2014
- 2014-11-30 IL IL235991A patent/IL235991A/en not_active IP Right Cessation
-
2016
- 2016-10-11 US US15/290,480 patent/US9884848B2/en not_active Expired - Fee Related